Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Terabe Website

Masaki Terabe, Ph.D.

Selected Publications

1)  Terabe M, Berzofsky JA.
The immunoregulatory role of type I and type II NKT cells in cancer and other diseases.
Cancer Immunol. Immunother. 63: 199-213, 2014.
2)  Izhak L, Berzofsky JA, Terabe M.
Balance is a key for happiness.
Oncoimmunology. 2: e24211, 2013.
3)  Berzofsky JA, Wood LV, Terabe M.
Cancer vaccines: 21st century approaches to harnessing an ancient modality to fight cancer.
Expert Rev Vaccines. 12: 1115-8, 2013.
4)  Izhak L, Ambrosino E, Kato S, Parish ST, O'Konek JJ, Weber H, Xia Z, Venzon D, Berzofsky JA, Terabe M.
Delicate balance among three types of T cells in concurrent regulation of tumor immunity.
Cancer Res. 73: 1514-23, 2013.
5)  Huang YH, Terabe M, Pendleton CD, Stewart Khursigara D, Bera TK, Pastan I, Berzofsky JA.
Identification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE.
PLoS ONE. 8: e64365, 2013.
6)  O'Konek JJ, Kato S, Takao S, Izhak L, Xia Z, Illarionov P, Besra GS, Terabe M, Berzofsky JA.
ß-Mannosylceramide Activates Type I Natural Killer T Cells to Induce Tumor Immunity without Inducing Long-Term Functional Anergy.
Clin. Cancer Res. 19: 4404-11, 2013.
7)  Berzofsky JA, Terabe M, Wood LV.
Strategies to use immune modulators in therapeutic vaccines against cancer.
Semin. Oncol. 39: 348-57, 2012.
8)  Nakashima H, Terabe M, Berzofsky JA, Husain SR, Puri RK.
A novel combination immunotherapy for cancer by IL-13Ra2-targeted DNA vaccine and immunotoxin in murine tumor models.
J. Immunol. 187: 4935-46, 2011.
9)  Yu H, Tawab-Amiri A, Dzutsev A, Sabatino M, Aleman K, Yarchoan R, Terabe M, Sui Y, Berzofsky JA.
IL-15 ex vivo overcomes CD4+ T cell deficiency for the induction of human antigen-specific CD8+ T cell responses.
J. Leukoc. Biol. 90: 205-14, 2011.
10)  Lai D, Zhu J, Wang T, Hu-Li J, Terabe M, Berzofsky JA, Clayberger C, Krensky AM.
KLF13 sustains thymic memory-like CD8(+) T cells in BALB/c mice by regulating IL-4-generating invariant natural killer T cells.
J. Exp. Med. 208: 1093-103, 2011.
11)  O'Konek JJ, Illarionov P, Khursigara DS, Ambrosino E, Izhak L, Castillo BF, Raju R, Khalili M, Kim HY, Howell AR, Besra GS, Porcelli SA, Berzofsky JA, Terabe M.
Mouse and human iNKT cell agonist ß-mannosylceramide reveals a distinct mechanism of tumor immunity.
J. Clin. Invest. 121: 683-94, 2011.
12)  Takaku S, Terabe M, Ambrosino E, Peng J, Lonning S, McPherson JM, Berzofsky JA.
Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells.
Int. J. Cancer. 126: 1666-74, 2010.
13)  Sui Y, Zhu Q, Gagnon S, Dzutsev A, Terabe M, Vaccari M, Venzon D, Klinman D, Strober W, Kelsall B, Franchini G, Belyakov IM, Berzofsky JA.
Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques.
Proc. Natl. Acad. Sci. U.S.A. 107: 9843-8, 2010.
14)  Oakley MS, Majam V, Mahajan B, Gerald N, Anantharaman V, Ward JM, Faucette LJ, McCutchan TF, Zheng H, Terabe M, Berzofsky JA, Aravind L, Kumar S.
Pathogenic roles of CD14, galectin-3, and OX40 during experimental cerebral malaria in mice.
PLoS ONE. 4: e6793, 2009.
15)  Terabe M, Ambrosino E, Takaku S, O'Konek JJ, Venzon D, Lonning S, McPherson JM, Berzofsky JA.
Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody.
Clin. Cancer Res. 15: 6560-9, 2009.
16)  Berzofsky JA, Terabe M.
The contrasting roles of NKT cells in tumor immunity.
Curr. Mol. Med. 9: 667-72, 2009.
17)  Berzofsky JA, Terabe M.
A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity.
Cancer Immunol. Immunother. 57: 1679-83, 2008.
18)  Nam JS, Terabe M, Mamura M, Kang MJ, Chae H, Stuelten C, Kohn E, Tang B, Sabzevari H, Anver MR, Lawrence S, Danielpour D, Lonning S, Berzofsky JA, Wakefield LM.
An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments.
Cancer Res. 68: 3835-43, 2008.
19)  Oh S, Perera LP, Terabe M, Ni L, Waldmann TA, Berzofsky JA.
IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis.
Proc. Natl. Acad. Sci. U.S.A. 105: 5201-6, 2008.
20)  Terabe M, Tagaya Y, Zhu Q, Granger L, Roederer M, Waldmann TA, Berzofsky JA.
IL-15 expands unconventional CD8alphaalphaNK1.1+ T cells but not Valpha14Jalpha18+ NKT cells.
J. Immunol. 180: 7276-86, 2008.
21)  Park JM, Terabe M, Donaldson DD, Forni G, Berzofsky JA.
Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation.
Cancer Immunol. Immunother. 57: 907-12, 2008.
22)  Berzofsky JA, Terabe M.
NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis.
J. Immunol. 180: 3627-35, 2008.
23)  Ambrosino E, Berzofsky JA, Terabe M.
Regulation of tumor immunity: the role of NKT cells.
Expert Opin Biol Ther. 8: 725-34, 2008.
24)  Fichtner-Feigl S, Terabe M, Kitani A, Young CA, Fuss I, Geissler EK, Schlitt HJ, Berzofsky JA, Strober W.
Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2.
Cancer Res. 68: 3467-75, 2008.
25)  Terabe M, Berzofsky JA.
The role of NKT cells in tumor immunity.
Adv. Cancer Res. 101: 277-348, 2008.
26)  Park JM, Terabe M, Steel JC, Forni G, Sakai Y, Morris JC, Berzofsky JA.
Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine.
Cancer Res. 68: 1979-87, 2008.
27)  Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA, Laurence A, Michalowska A, Mamura M, Lonning S, Berzofsky JA, Wakefield LM.
Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17.
Cancer Res. 68: 3915-23, 2008.
28)  Ambrosino E, Terabe M, Halder RC, Peng J, Takaku S, Miyake S, Yamamura T, Kumar V, Berzofsky JA.
Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis.
J. Immunol. 179: 5126-36, 2007.
29)  Terabe M, Berzofsky JA.
NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis.
Trends Immunol. 28: 491-6, 2007.
30)  Toubaji A, Hill S, Terabe M, Qian J, Floyd T, Simpson RM, Berzofsky JA, Khleif SN.
The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection.
Vaccine. 25: 5882-91, 2007.
31)  Terabe M, Khanna C, Bose S, Melchionda F, Mendoza A, Mackall CL, Helman LJ, Berzofsky JA.
CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta.
Cancer Res. 66: 3869-75, 2006.
32)  Kawakami K, Terabe M, Kawakami M, Berzofsky JA, Puri RK.
Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain.
Cancer Res. 66: 4434-42, 2006.
33)  Kawakami K, Terabe M, Kioi M, Berzofsky JA, Puri RK.
Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors.
Clin. Cancer Res. 12: 4678-86, 2006.
34)  Okazaki T, Terabe M, Catanzaro AT, Pendleton CD, Yarchoan R, Berzofsky JA.
Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice.
J. Virol. 80: 10645-51, 2006.
35)  Terabe M, Swann J, Ambrosino E, Sinha P, Takaku S, Hayakawa Y, Godfrey DI, Ostrand-Rosenberg S, Smyth MJ, Berzofsky JA.
A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance.
J. Exp. Med. 202: 1627-33, 2005.
36)  Park JM, Terabe M, Sakai Y, Munasinghe J, Forni G, Morris JC, Berzofsky JA.
Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas.
J. Immunol. 174: 4228-36, 2005.
37)  Pinto LA, Trivett MT, Wallace D, Higgins J, Baseler M, Terabe M, Belyakov IM, Berzofsky JA, Hildesheim A.
Fixation and cryopreservation of whole blood and isolated mononuclear cells: Influence of different procedures on lymphocyte subset analysis by flow cytometry.
Cytometry B Clin Cytom. 63: 47-55, 2005.
38)  Berzofsky JA, Oh S, Terabe M.
Peptide vaccines against cancer.
Cancer Treat. Res. 123: 115-36, 2005.
39)  Park JM, Terabe M, van den Broeke LT, Donaldson DD, Berzofsky JA.
Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13.
Int. J. Cancer. 114: 80-7, 2005.
40)  Oh S, Terabe M, Pendleton CD, Bhattacharyya A, Bera TK, Epel M, Reiter Y, Phillips J, Linehan WM, Kasten-Sportes C, Pastan I, Berzofsky JA.
Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells.
Cancer Res. 64: 2610-8, 2004.
41)  Terabe M, Berzofsky JA.
Immunoregulatory T cells in tumor immunity.
Curr. Opin. Immunol. 16: 157-62, 2004.
42)  Terabe M, Wakana S, Katakura K, Onodera T, Matsumoto Y, Ito M.
Influence of H2 complex and non-H2 genes on progression of cutaneous lesions in mice infected with Leishmania amazonensis.
Parasitol. Int. 53: 217-21, 2004.
43)  Berzofsky JA, Ahlers JD, Janik J, Morris J, Oh S, Terabe M, Belyakov IM.
Progress on new vaccine strategies against chronic viral infections.
J. Clin. Invest. 114: 450-62, 2004.
44)  Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC.
Progress on new vaccine strategies for the immunotherapy and prevention of cancer.
J. Clin. Invest. 113: 1515-25, 2004.
45)  Terabe M, Park JM, Berzofsky JA.
Role of IL-13 in regulation of anti-tumor immunity and tumor growth.
Cancer Immunol. Immunother. 53: 79-85, 2004.
46)  Sakai Y, Morrison BJ, Burke JD, Park JM, Terabe M, Janik JE, Forni G, Berzofsky JA, Morris JC.
Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
Cancer Res. 64: 8022-8, 2004.
47)  Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD, Chen W, Wahl SM, Ledbetter S, Pratt B, Letterio JJ, Paul WE, Berzofsky JA.
Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.
J. Exp. Med. 198: 1741-52, 2003.
48)  Ahlers JD, Belyakov IM, Terabe M, Koka R, Donaldson DD, Thomas EK, Berzofsky JA.
A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L.
Proc. Natl. Acad. Sci. U.S.A. 99: 13020-5, 2002.
49)  Ostrand-Rosenberg S, Clements VK, Terabe M, Park JM, Berzofsky JA, Dissanayake SK.
Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent.
J. Immunol. 169: 5796-804, 2002.
50)  Terabe M, Kuramochi T, Ito M, Hatabu T, Sanjoba C, Chang KP, Onodera T, Matsumoto Y.
CD4(+) cells are indispensable for ulcer development in murine cutaneous leishmaniasis.
Infect. Immun. 68: 4574-7, 2000.
51)  Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA.
NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway.
Nat. Immunol. 1: 515-20, 2000.
52)  Terabe M, Shimizu M, Mabuchi A, Matui S, Morikawa H, Kaneda K, Kakiuchi T, Yokomuro K.
Unresponsiveness of intrahepatic lymphocytes to bacterial superantigen: rapid development of suppressive Mac-1(high) cells in the mouse liver.
Hepatology. 32: 507-13, 2000.
53)  Matsui S, Ahlers JD, Vortmeyer AO, Terabe M, Tsukui T, Carbone DP, Liotta LA, Berzofsky JA.
A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.
J. Immunol. 163: 184-93, 1999.
54)  Terabe M, Hatabu T, Takahashi H, Ito M, Onodera T, Matsumoto Y.
Leishmania amazonensis infection in nude mice.
Exp. Anim. 48: 119-23, 1999.
55)  Terabe M, Kuramochi T, Hatabu T, Ito M, Ueyama Y, Katakura K, Kawazu S, Onodera T, Matsumoto Y.
Non-ulcerative cutaneous lesion in immunodeficient mice with Leishmania amazonensis infection.
Parasitol. Int. 48: 47-53, 1999.
56)  Matsui S, Terabe M, Mabuchi A, Takahashi M, Saizawa M, Tanaka S, Yokomuro K.
A unique response to staphylococcal enterotoxin B by intrahepatic lymphocytes and its relevance to the induction of tolerance in the liver.
Scand. J. Immunol. 46: 230-4, 1997.
Click Here to View Collapsed Bibliography.

This page was last updated on 4/15/2014.